INTRODUCTION
Abdominoplasty is the sixth most commonly performed proce dure in cosmetic surgery, with 117,158 cases in 2014 in the US alone [1] . Possible postoperative complications include infec tion, hemorrhage, neurologic and thrombotic disorders. Venous thromboembolism (VTE), a spectrum of diseases ranging from deep venous thrombosis (DVT) to pulmonary embolism (PE), is a major source of morbidity and mortality for these hospital ized patients. The majority of DVT cases described in the plas tic surgery literature involve abdominoplasty [2] . As a conse quence, DVT risk assessment and adequate prophylaxis are of paramount importance. In 2012, the ASPS Venous Thrombo embolism Task Force Report developed recommendations for thromboembolism prevention [3] in the plastic surgery setting. Nevertheless, as stated by Murphy et al. [3] , there is currently a lack of evidence regarding the type, dosage, timing, and length of the prophylaxis. The aim of the present study is to address these variables by describing our protocol and its outcomes in 253 abdominoplasty patients.
METHODS
The comprehensive DVT prophylaxis protocol was applied to 253 patients undergoing abdominoplasty (conventional abdo minoplasty with rectus muscle plication [4] ) at the Department of Plastic Reconstructive and Aesthetic Surgery of our institu tion between January 2008 and January 2013 (Table 1) . Patients with a body mass index (BMI) between 30 and 40 were not considered eligible for surgery until the BMI was reduced to 30 or less, except in cases of severe abdominal hernia or with high risk of strangulation. Preoperatively, the patient underwent a complete physical examination with special attention to the pres ence of varicose veins or swollen legs; furthermore, anamnesis focused on previous abortions, inherited thrombophilic and metabolic diseases (if known), as well as on drug intake. Intra operatively, all patients underwent passive mechanical throm boprophylaxis, and the knees were flexed to facilitate blood flow through the popliteal veins. Postoperative measures and criteria for enoxaparin administration are described in Table 1 . Patients clinically suspected of developing DVT underwent ultrasound color Doppler sonography. Clinical suspicion was defined by the onset of swelling, pain, warmth, or redness in one leg. Pa tients were analyzed for age, BMI, enoxaparin dose, risk factors (oral contraceptive or estrogen therapy intake, hypertension, smoking, diabetes) and complications (hematoma, thrombosis, seroma, wound dehiscence). Followup ranged from 6 months to 5 years. Statistical analyses were performed with IBM SPSS ver. 20 (IBM Corp., Armonk, NY, USA). Spearman's correlation coefficient was performed to test the possible correlations among age, BMI, enoxaparin administration, risk factors, and complica tions; Fisher's exact test was performed to test the possible cor relations between complications and risk factors or enoxaparin administration; the null hypothesis of the MannWhitney U test was that the distribution of complications was the same among the enoxaparin dosages and vice versa; univariate analysis of variance was performed with the complications groups. Only P values lower than 0.05 were considered as statistically significant.
RESULTS
The protocol was applied to 253 abdominoplasty patients. The mean age was 44 (ranging from 21 to 72), the average BMI was 26.4 (ranging from 17 to 40). Among the patients, 166 (65.6%) had previously undergone a bariatric procedure. Nineteen pa tients (7.5%) had a previous diagnosis of diabetes, 19 (7.5%) suffered from hypertension, 77 (30.4%) smoked, 44 (17.3%) took hormonal therapy. Mean operative time was 115 minutes. Regarding drug administration, 144 patients received enoxapa rin, while 106 did not ( Diabetes, estrogen intake, hypertension, thrombophilic diseases, and smoking. Table 3 . DVT was documented by the mean of ultrasound color Doppler sonography in two (0.8%) of the four patients who were clinically suspected (both gastrocnemius veins of the left leg were involved in one patient, while the lateral gastrocnemius vein of the left leg and ipsilateral saphenofemoral junction were involved in the other one). Statistical analysis showed no signifi cant correlation between enoxaparin administration and hema toma (P = 0.07), DVT (P > 0.99), seroma (P > 0.99), or necro sis (P = 0.17). Consistently, there was no correlation between enoxaparin dosage and hematoma (P = 0.18), DVT (P = 0.61), seroma (P = 0.7), or necrosis (P = 0.12). No statistically signifi cant correlation was found between any risk factor and compli cations.
DISCUSSION
The number of patients suffering from excess skin after massive weight loss is dramatically increasing in western societies, caus ing physical, psychological, and social difficulties [5] . Surgical resection by abdominoplasty is the only effective treatment to reduce abdominal skin excess. As a consequence, abdomino plasty is a commonly sought after procedure in plastic surgery [1] . Several articles discussed the complications following ab dominoplasty [6, 7] : VTE, a spectrum of diseases ranging from DVT to PE, is a major source of morbidity and mortality for these patients. DVT is a dreadful complication. It may be initial ly asymptomatic and then evolve into PE, with 10 percent fatal within 1 hour of first symptoms. It can also induce permanent damage to venous valves, resulting in a chronically swollen in fectionprone extremity, known as postthrombotic syndrome [8] . The majority of VTE cases described in the plastic surgery literature involve abdominoplasty [2] . In 2012, a systematic re view of outcomes found VTE to be its major complication, with 2%-8% incidence in three retrospective studies [9] . Recently, Winocour et al. [10] reported a 0.8% incidence of suspected or confirmed VTE following a tummy tuck. While many other surgical specialties have published specific guidelines on throm boprophylaxis, plastic surgery has not. In 2011, the American Society of Plastic and Reconstructive Surgeons proposed a task force on VTE: Murphy et al. [3] defined uptodate recommen dations but, as they stated in their article, there was not enough evidence in the literature to write exhaustive guidelines regard ing the medication, dosage, timing, or length of the prophylaxis. Our thromboembolism prevention protocol specifically ad dresses these variables. Enoxaparin is a pharmacologically well known and easytomanage anticoagulant. Specifically, it has been shown to reduce the incidence of postoperative DVT and PE in plastic surgery patients, with contrasting results for the risk of postoperative bleeding [11, 12] . Several other medica tions, such as rivaroxaban, have not been found to be safe or reli able for thromboprophylaxis in our surgical specialty [13] and, consequently, enoxaparin is the most widely used anticoagulant [3] . In our protocol, its dosage is adapted on the BMI, as this is among the strongest risk factors in this surgical setting: large ep idemiologic studies have demonstrated a significant correlation between BMI and VTE risk [14] . Optimal timing of chemopro phylaxis remains controversial. As reported by Seruya and Baker [8] , 50% of deep venous thromboses start intraoperatively as a consequence of the vasodilatory effect of general anesthesia, im mobilization, supine position, and personal risk factors. Colwell et al. [15] found a significant increase in thrombin generation intraoperatively. Thus, prophylaxis must be working at that time. Nevertheless, it was demonstrated that preoperative ad ministration of chemoprophylaxis resulted in increased bleed ing without improved efficacy compared to 6hour postopera tive first administration [16] . As a consequence, we used passive mechanical thromboprophylaxis intraoperatively and started enoxaparin in the early postoperative period. Furthermore, rec tus muscle plication increases intraabdominal pressure [17] , thus decreasing venous return and predisposing the patient to DVT [18] ; hence, enoxaparin administration cannot be limited to the early postoperative period and, in our protocol, it is pre scribed for 7 days. Risk assessment is also crucial. Appropriate assessment models have been identified in several surgical spe cialties to guide perioperative thromboprophylaxis: the ASPS Venous Thromboembolism Task Force Report [3] selected the 2005 Caprini RiskAssessment Module (RAM) as the reference point to stratify plastic surgery patients. This risk score was not used in our cohort of patients, as we introduced it in our clinical practice from January 2013. Nevertheless, by retrospectively an alyzing data for the patients that received enoxaparin in this study, we found that all of them had a Caprini RAM score of 3 or more, which is, according to Murphy et al. [3] the cutoff to consider the use of chemoprophylaxis. We would like to highlight the concept that an adequate thromboprophylaxis protocol should [19] . Smoking cessation three months to four weeks before surgery reduces the incidence of intraoper ative and postoperative cardiovascular events [20] . Moreover, in our experience, active participation of the patient in reducing his own risk factors stimulates the patient's motivational drive, thus leading to healthier lifestyle and improved postoperative weight control [21] . In 2012, a systematic review performed by Staalesen et al. [9] found that VTE following abdominoplasty had an incidence of 2%-8% in three studies. Hatef et al. [12] re ported a 4.65% incidence of VTE events when abdominoplasty was performed as a single procedure. The protocol described here resulted in a 0.8% incidence of DVT and no PE, thus prov ing it effective in reducing the incidence of VTE events. VTE is a devastating complication, with high morbidity and mortality. Adequate prophylaxis is of paramount importance for patients' safety. Unfortunately, to date, there is not enough evidence in the plastic surgery literature to make allinclusive recommenda tions. Specifically, the type, dosage, timing, and length of the chemoprophylaxis are currently under debate. Our protocol specifically addressed these variables. It proved to be effective in thrombotic event prevention with an acceptable risk of hemor rhagic complications. However, larger multicenter, randomized studies would be needed to elaborate definitive guidelines.
